Pangaea OncologyXMAD:PANG 63 Days Payable is 2,578.95 as of Dec. 2025, which is 47% below its 10-year median of 4,854.32. GuruFocus rates XMAD:PANG with a GF Score™ of 63/100 and a GF Value™ of €2.16 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 192 Medical Diagnostics & Research companies, Pangaea Oncology ranks better than 98.96% on this metric.
The historical rank and industry rank for Pangaea Oncology's Days Payable or its related term are showing as below:
XMAD:PANG'
s Days Payable Range Over the Past 10 Years
Min: 1139.91 Med: 4854.32 Max: 8568.73
Current: 7898.97
During the past 13 years, Pangaea Oncology's highest Days Payable was 8568.73. The lowest was 1139.91. And the median was 4854.32.
XMAD:PANG's Days Payable is ranked better than 98.96% of 192
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.385
vs XMAD:PANG: 7898.97
Pangaea Oncology's Days Payable
declined
from Dec. 2024 (6,754.05) to Dec. 2025 (2,578.95).
It may suggest that Pangaea Oncologyaccelerated paying its suppliers.
Pangaea Oncology Days Payable Related Terms
Pangaea Oncology Days Payable Historical Data
* Premium members only.
The historical data trend for Pangaea Oncology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:PANG vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Pangaea Oncology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pangaea Oncology Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pangaea Oncology's Days Payable distribution charts can be found below:
* The bar in red indicates where Pangaea Oncology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pangaea Oncology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pangaea Oncology (XMAD:PANG) has a Days Payable of 2,578.95 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pangaea Oncology and its competitors. This is 47% below median its historical median of 4,854.32. Over the past decade, Pangaea Oncology's Days Payable has ranged from 1,139.91 to 8,568.73. According to the industry distribution chart, Pangaea Oncology ranks #2 out of 192 companies in the Medical Diagnostics & Research industry, placing it in the top 1%.
Is Pangaea Oncology's Days Payable too high?
Pangaea Oncology's current Days Payable of 2,578.95 is 47% below median its 10-year median of 4,854.32. Over the past 10 years, this metric has ranged from a low of 1,139.91 to a high of 8,568.73. The Medical Diagnostics & Research industry median Days Payable is 65.39. Pangaea Oncology's value of 2,578.95 is 3844.3% above this industry median. Based on the distribution chart, Pangaea Oncology ranks #2 out of 192 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Pangaea Oncology has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pangaea Oncology's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pangaea Oncology ranks #2 out of 192 companies for Days Payable. This places Pangaea Oncology in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 65.39. Pangaea Oncology's value of 2,578.95 is 3844.3% above this benchmark. Historically, Pangaea Oncology's own Days Payable has ranged from 1,139.91 to 8,568.73 over the past decade. While the company's 10-year median is 4,854.32 vs. the industry median of 65.39, Pangaea Oncology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.39, based on 192 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pangaea Oncology's current Days Payable of 2,578.95 is 3844.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pangaea Oncology and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pangaea Oncology's current Days Payable is 2,578.95, which is 47% below median its own 10-year median of 4,854.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pangaea Oncology stock overvalued right now?
Based on GuruFocus' analysis, Pangaea Oncology (XMAD:PANG) is currently considered Possible Value Trap. The stock's GF Value™ is €2.16, compared to a current price of €1.51 — trading 30.1% below its estimated fair value. The current Days Payable is 2,578.95, which is 47% below median its 10-year median of 4,854.32 and 3844.3% above the Medical Diagnostics & Research industry median of 65.39. Pangaea Oncology's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pangaea Oncology (XMAD:PANG), the current Days Payable is 2,578.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pangaea Oncology (XMAD:PANG) Overvalued in 2026?
Based on GuruFocus' analysis, Pangaea Oncology stock appears to be undervalued.
The current stock price of €1.51 is trading 30.1% below its estimated GF Value™ of €2.16.
GuruFocus considers Pangaea Oncology to be Possible Value Trap.
Key valuation signals for XMAD:PANG:
Days Payable: 2,578.95 (47% below median its 10-year median of 4,854.32)
GF Value™: €2.16 vs. price of €1.51 (30.1% below fair value)
Industry Position: 3844.3% above the Medical Diagnostics & Research median (#2 of 192)
No single metric tells the full story. See the XMAD:PANG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.
63GF Score
Get the complete analysis for XMAD:PANG
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PANG has been successfully added to your 
